Clostridium Difficile-Associated Diarrhea News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Can Probiotics Prevent C. difficile-Associated Diarrhea? - Monthly Prescribing Reference



Can Probiotics Prevent C. difficile-Associated Diarrhea? 
Monthly Prescribing Reference
Probiotics may be effective for preventing C. difficile-associated diarrhea (CDAD), based on results from a new systematic review and meta-analysis. For this study, researchers searched PubMed, EMBASE, CENTRAL, and the Cochrane IBD Group Specialized ...

 


Meropenem/Vaborbactam for Complicated UTIs - ModernMedicine



Meropenem/Vaborbactam for Complicated UTIs 
ModernMedicine
The most frequently reported adverse effects associated with MER/VAB included headache, phlebitis/infusion site reactions, and diarrhea. Hypersensitivity reactions occurred in 1.8% of patients in this trial, and thus MER/VAB is contraindicated in ...

 


Optimer Pharmaceuticals (OPTR) & Sonoma Pharmaceuticals (SNOA) Head-To-Head Review - Dispatch Tribunal



Optimer Pharmaceuticals (OPTR) & Sonoma Pharmaceuticals (SNOA) Head-To-Head Review 
Dispatch Tribunal
On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist ...

and more » 


Comparing Onconova Therapeutics (NASDAQ:ONTX) & Optimer Pharmaceuticals (OPTR) - TrueBlueTribune



Comparing Onconova Therapeutics (NASDAQ:ONTX) & Optimer Pharmaceuticals (OPTR) 
TrueBlueTribune
On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist ...

and more » 


Critical Review: Optimer Pharmaceuticals (OPTR) versus Sonoma Pharmaceuticals (SNOA) - The Ledger Gazette



Critical Review: Optimer Pharmaceuticals (OPTR) versus Sonoma Pharmaceuticals (SNOA) 
The Ledger Gazette
... its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA ...

and more » 


Analyzing Anika Therapeutics (ANIK) and Optimer Pharmaceuticals (OPTR) - The Lincolnian Online



Analyzing Anika Therapeutics (ANIK) and Optimer Pharmaceuticals (OPTR) 
The Lincolnian Online
... its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA ...

and more » 


Contrasting Onconova Therapeutics (NASDAQ:ONTX) and Optimer Pharmaceuticals (OPTR) - The Ledger Gazette



Contrasting Onconova Therapeutics (NASDAQ:ONTX) and Optimer Pharmaceuticals (OPTR) 
The Ledger Gazette
On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist ...

 


Critical Review: Sonoma Pharmaceuticals (SNOA) vs. Optimer Pharmaceuticals (OPTR) - The Lincolnian Online



Critical Review: Sonoma Pharmaceuticals (SNOA) vs. Optimer Pharmaceuticals (OPTR) 
The Lincolnian Online
On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist ...
Financial Newsletter - Zacks Investment Research Zacks Investment Research

all 18 news articles » 


Analyzing Onconova Therapeutics (ONTX) and Optimer Pharmaceuticals (OPTR) - Week Herald



Analyzing Onconova Therapeutics (ONTX) and Optimer Pharmaceuticals (OPTR) 
Week Herald
On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist ...

and more » 


Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Optimer Pharmaceuticals (NASDAQ:OPTR) - The Lincolnian Online



Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Optimer Pharmaceuticals (NASDAQ:OPTR) 
The Lincolnian Online
On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist ...

and more »